Biotech Values

[mouton29]

That’s why they emphasize how large the first booster market is (in theory):

“According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose.1 Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults. Novavax is also conducting ongoing trials further exploring the immunogenicity and safety of the Novavax COVID-19 Vaccine, Adjuvanted to expand its use as a booster.”